What We're Reading: Page 325
Industry reads hand-picked by our editors
Oct 13, 2016
-
Nature
Safety concerns blight promising cancer therapy
-
Bloomberg
The man behind India's best stock faces his biggest test
-
Boston Business Journal
R&D spending takes a back seat to other costs at Boston’s biggest biotechs
-
New York Times
Drug coupons: Helping a few at the expense of everyone
Oct 12, 2016
Oct 11, 2016
-
BloombergGadfly
Bristol's failure of leadership
-
The New York Times
Theranos sued by investor who accuses it of securities fraud
-
The San Diego Union-Tribune
Illumina plummets on lowered revenue guidance
-
The Street
Even high-flying Tesaro and its ovarian cancer drug has a bear thesis
-
Reuters
Doctors grapple with best use of potent new cancer drugs
Oct 10, 2016
-
Reuters
Bristol drug flop opens big cancer opportunity: AstraZeneca CEO
-
Renaissance Capital
Gene editing biotech CRISPR Therapeutics sets terms for $75 million IPO
-
SupplyChain Dive
Are pharmaceutical supply chains ill-regulated?
-
The Wall Street Journal
Insulin prices soar while drugmakers' share stays flat
Oct 07, 2016
-
BioWorld
European biopharma funding is down 43% so far this year
-
Stat
Whether it’s Trump or Clinton, biotech is in for ‘a moment of change’
-
Science
Why are people fighting over a promising treatment for a fatal childhood disease?
-
The Wall Street Journal
Pfizer to sell New York City headquarters by end of next year
Previous
